Posted by Michael Wonder on 21 Dec 2020
European Commission approves Aimmune’s Palforzia as first-ever treatment for peanut allergy in the EU
21 December 2020 - Peanut allergy is one of the most common food allergies in Europe.
Aimmune Therapeutics today announced that the European Commission has approved Palforzia [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of patients with peanut allergy.
Palforzia is indicated in patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet and may be continued in patients 18 years of age and older.
